Der Nervenarzt

, Volume 75, Issue 8, pp 749–754 | Cite as

Levetiracetam in der Kombinationsbehandlung fokaler Epilepsien

Erfahrungen bei 80 Patienten
  • Andreas Schulze-Bonhage
  • B. Feil
  • S. Fauser
  • V. Homberg
Originalien

Zusammenfassung

Hintergrund

Levetiracetam wurde im Jahre 2000 in Deutschland als Antikonvulsivum zur Zusatztherapie fokaler Epilepsien zugelassen. Die Effektivität und Verträglichkeit wird in der vorliegenden retrospektiven Analyse untersucht.

Methoden

Bei 80 konsekutiv mit Levetiracetam add-on behandelten Patienten mit fokalen Epilepsien wurde der Effekt von Levetiracetam auf die Anfallsfrequenz sowie die Inzidenz von Nebenwirkungen untersucht.

Ergebnisse

Bei einem mittleren Follow-up-Zeitraum von 12,3 Monaten wurde bei 18,8% der mit Levetiracetam behandelten Patienten Anfallsfreiheit erzielt, bei 15,0% eine Anfallsreduktion um mindestens 75% und bei weiteren 3,8% um mindestens 50%. Eine Dosissteigerung über 3500 mg/Tag hinaus führte nicht zu einer Steigerung der Effektivität, ging jedoch mit einem erhöhten Risiko paradoxer Effekte auf die Anfallsfrequenz und psychischer Nebenwirkungen einher. Levetiracetam war wirksam gegen alle Anfallstypen und unabhängig von der Fokuslokalisation. Ein Wirkverlust bei längerer Behandlungsdauer war selten. Häufigste unerwünschte Effekte der Therapie stellten Somnolenz und Aggressivität dar; eine rasche Eindosierung beeinträchtigte die Verträglichkeit nicht.

Schlussfolgerung

Levetiracetam stellt ein potentes, gut handhabbares und überwiegend gut verträgliches Antikonvulsivum dar, mit dem auch auch bei schwierig therapierbaren Patienten mit fokalen Epilepsien eine deutliche Anfallsreduktion oder Anfallsfreiheit erzielt werden können.

Schlüsselwörter

Fokale Epilepsie Levetiracetam Kombinationsbehandlung Effektivität Verträglichkeit 

Levetiracetam in combined therapy for focal epilepsy: experience with 80 patients

Abstract

Background

Levetiracetam was released in 2000 as an antiepileptic drug for add-on treatment of focal epilepsies. Its efficacy and tolerability were investigated in this retrospective study.

Methods

The effects of add-on treatment with levetiracetam on seizure frequency and side effects were analyzed retrospectively in 80 consecutive patients with focal epilepsy.

Results

With a mean follow-up of 12.3 months, 18.8% of patients treated with levetiracetam became seizure-free, and additional 15.0% and 3.8% had reductions in seizure frequency of 75% and 50%, respectively. Increasing the dosage to more than 3,500 mg/day did not improve efficacy but could induce a paradoxical increase in seizure frequency and psychic side effects. Levetiracetam was efficacious against all seizure types independently of focus localization. There was no evidence for the development of tolerance with longer periods of treatment. The most common adverse effects were somnolence and aggressiveness; tolerability did not decrease with rapid titration.

Conclusions

Levetiracetam is a potent and generally well tolerable new antiepileptic drug which is also efficacious in patients with difficult-to-treat focal epilepsies.

Key words

Focal epilepsy Levetiracetam Combination therapy Efficacy Tolerability 

Literatur

  1. 1.
    Abou-Khalil B, Hemdal P, Privitera MD (2003) An open-label study of levetiracetam at individualised doses between 1,000 and 3,000 mg day−1 in adult patients with refractory epilepsy. Seizure 12:141–149CrossRefPubMedGoogle Scholar
  2. 2.
    Bazil CW, Rose A, Resor S et al. (2002) Levetiracetam may be more effective for late-onset partial epilepsy. Arch Neurol 59:1905–1908CrossRefPubMedGoogle Scholar
  3. 3.
    Bello-Espinosa LE, Roberts SL (2003) Levetiracetam for benign epilepsy of childhood with centrotemporal spikes—three cases. Seizure 12:157–159CrossRefPubMedGoogle Scholar
  4. 4.
    Ben-Menachem E, Falter U (2000) Efficacy and tolerability of levetiracetam 3,000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41:1276–1283PubMedGoogle Scholar
  5. 5.
    Ben-Menachem E, Edrich P, van Vleymen B et al. (2003) Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53:57–64CrossRefPubMedGoogle Scholar
  6. 6.
    Betts T, Waegemans T, Crawford P (2000) A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000 mg daily and 4,000 mg daily, without titration in patients with refractory epilepsy. Seizure 9:80–87CrossRefPubMedGoogle Scholar
  7. 7.
    Betts T, Yarrow H, Greenhill L et al. (2003) Clinical experience of marketed Levetiracetam in an epilepsy clinic—a one year follow up study. Seizure 12:136–140CrossRefPubMedGoogle Scholar
  8. 8.
    Bialer M, Johannessen SI, Kupferberg HJ et al. (2002) Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 51:31–71CrossRefPubMedGoogle Scholar
  9. 9.
    Boon P, Chauvel P, Pohlmann-Eden B et al. (2002) Dose-response effect of levetiracetam 1,000 and 2,000 mg/day in partial epilepsy. Epilepsy Res 48:77–89Google Scholar
  10. 10.
    Cereghino JJ, Biton V, Abou-Khalil B et al. (2000) Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 55:236–242CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen J (2003) Levetiracetam monotherapy for primary generalised epilepsy. Seizure 12:150–153CrossRefPubMedGoogle Scholar
  12. 12.
    Cramer JA, DeRue K, Devinsky O et al. (2003) A systematic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epil Behav 4:124–132CrossRefGoogle Scholar
  13. 13.
    Dinkelacker V, Dietl T, Widman G et al. (2003) Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epil Behav 4:537–547CrossRefGoogle Scholar
  14. 14.
    French J, Edrich P, Cramer JA (2001) A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 47:77–90CrossRefPubMedGoogle Scholar
  15. 15.
    Gates JR, Folland C, Berhovw J et al. (2002) Behavioral side-effects of levetiracetam. Epilepsia 43(S7):187Google Scholar
  16. 16.
    Gelisse P, Crespel A, Genton P et al. (2003) Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 107:302–303PubMedGoogle Scholar
  17. 17.
    Glauser TA, Pellock JM, Bebin EM et al. (2002) Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518–524CrossRefPubMedGoogle Scholar
  18. 18.
    Glien M, Brandt C, Potschka H et al. (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43:350–357CrossRefPubMedGoogle Scholar
  19. 19.
    Gower AJ, Hirsch E, Boehrer A et al. (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22:207–213CrossRefPubMedGoogle Scholar
  20. 20.
    Grant R, Shorvon SD (2000) Efficacy and tolerability of 1,000–4,000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 42:89–95CrossRefPubMedGoogle Scholar
  21. 21.
    Harden C (2001) Safety profile of levetiracetam. Epilepsia 42(S4):36–39CrossRefGoogle Scholar
  22. 22.
    Klitgaard H, Matagne A, Gobert J et al. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191–206PubMedGoogle Scholar
  23. 23.
    Kossoff EH, Bergey GK, Freeman J et al. (2001) Levetiracetam psychosis in children with epilepsy. Epilepsia 42:1611–1613CrossRefPubMedGoogle Scholar
  24. 24.
    Krakow K, Walker M, Otoul C et al. (2001) Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56:1772–1774PubMedGoogle Scholar
  25. 25.
    Löscher W, Hönack D (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232:147–158CrossRefPubMedGoogle Scholar
  26. 26.
    Matagne AC, Baltes E, Coupez R et al. (2001) Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in audiogenic susceptible mice. Epilepsia 42(S7):82Google Scholar
  27. 27.
    Morrell MJ, Leppik I, French J et al. (2003) The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54:153–161CrossRefPubMedGoogle Scholar
  28. 28.
    Noyer M, Gillard M, Matagne A et al. (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137–146PubMedGoogle Scholar
  29. 29.
    Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: towards ideal characteristics. Pharmacol Therap 85:77–85CrossRefGoogle Scholar
  30. 30.
    Perrucca E, Gidal BE, Baltès E (2003) Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive theapy trials. Epilepsy Res 53:47–56CrossRefPubMedGoogle Scholar
  31. 31.
    Rijckevorsel K (2001) The ‘number needed to treat’ with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 10:235–26CrossRefPubMedGoogle Scholar
  32. 32.
    Sadek A, Fix A, French J (2002) Levetiracetam-related behavioural adverse effects: a post-marketing study. Epilepsia 43(S8):151Google Scholar
  33. 33.
    Schmidt D, Elger CE, Holmes GL (2002) Pharmacological over-treatment in epilepsy. Epilepsy Res 51:1-12CrossRefPubMedGoogle Scholar
  34. 34.
    Sharief M, Singh P, Sander J et al. (1996) Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 9:106–112CrossRefGoogle Scholar
  35. 35.
    Shorvon SD, Löwenthal A, Janz D et al. (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41:1179–1186PubMedGoogle Scholar
  36. 36.
    Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67:351–384CrossRefPubMedGoogle Scholar
  37. 37.
    White JR; Walczak TS, Leppik IE et al. (2003) Discontinuation of levetiracetam because of behavioural side effects. Neurology 61:1218–1221PubMedGoogle Scholar
  38. 38.
    Zona C, Niespodziany I, Marchetti C et al. (2001) Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 10:279–286CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Andreas Schulze-Bonhage
    • 1
    • 2
  • B. Feil
    • 1
  • S. Fauser
    • 1
  • V. Homberg
    • 1
  1. 1.EpilepsiezentrumUniversitätsklinikum FreiburgFreiburgDeutschland
  2. 2.EpilepsiezentrumNeurozentrum des Universitätsklinikums FreiburgFreiburgDeutschland

Personalised recommendations